Angelini Pharma appoints Rafal Kaminski as new Chief Scientific Officer

AP Site22 1030X302 Kaminski
  • Published: 13 Jan 2022
  • Rafal Kaminski as Chief Scientific Officer will lead Angelini Pharma’s future pipeline development and research and innovation model
  • He previously served as Chief Scientific Officer at OncoAndredi Therapeutics and held international senior R&D leadership positions with UCB and Roche

Rome, 13 January 2021 – Angelini Pharma, an international pharmaceutical company which is part of the privately-owned Angelini Industries, has appointed Rafal Kaminski as its new Chief Scientific Officer. Rafal Kaminski has broad international experience in drug discovery and innovation and will lead Angelini Pharma’s research and development (R&D) strategy. He will commence his role in January 2022.

I am excited for Rafal’s appointment which completes our leadership team. He will be instrumental in enabling us to developing a solid leadership in the field of brain health and rare diseases” commented Pierluigi Antonelli, Chief Executive Officer Angelini Pharma. “Rafal brings a significant wealth of experience having led R&D from discovery to clinical development of small innovative molecules. He will be responsible for driving our current and future pipeline development strategy, including our distinctive research and innovation model”.
Over the past 15 years, Rafal Kaminski has held senior R&D leadership roles at UCB Pharma in Belgium and Roche in Switzerland. He joins Angelini Pharma from OncoAndredi Therapeutics, a leading biotech company in Poland where he served as Chief Scientific Officer and Board Member.

I am very pleased to be joining Angelini Pharma and help further its research and innovation” commented Rafal Kaminski. “Angelini Pharma has an exciting pipeline across a broad range of therapeutic areas, and I am keen to leverage my experience and to lead the accomplished R&D team collaborating with the leadership team.

Rafal Kaminski received his medical degree and doctorate in pharmacology from the Medical University of Lublin, Poland and completed his post-doctoral training at Radboud University in The Netherlands and in the National Institutes of Health in the U.S. He obtained a Diploma in Pharmaceutical Medicine from ULB in Belgium.

For more information, contact:
Daniela Poggio, Angelini Pharma Executive Director Global Communications
daniela.poggo@angelinipharma.com